Paying for drug approvals - Who's using whom?

New England Journal of Medicine

Volumn 356, Issue 17, 2007, Pages 1697-1700

  Avorn, Jerry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMMUNITY HOSPITAL; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; MEDICAL EDUCATION; PRIORITY JOURNAL; REVIEW;

EID: 34247463760     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp078041     Document Type: Article

References (5)

1. Carpenter D, Bowers J, Grimmer J, Moffitt S, Nall C, Zucker EJ. Deadline effects in drug regulatory review. Robert Wood Johnson Scholars in Health Policy Research Program, Working Paper Series, February 2007. (Accessed April 5, 2007, at http://www.healthpolicyscholars.org/sub-news/working_papers/ working_paper_35.htm.)
2. Food and Drug Administration. Prescription drug user fee act. Fed Regist 2007;72:1743-53.
3. Drug safety: improvement needed in FDA's postmarket decision-making and oversight process. Washington, DC: Government Accountability Office, 2006. (Document no. GAO-06-402.)
4. Committee on the Assessment of the US Drug Safety System, Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2006.
5. Angell M, Avorn J, Bingham E, et al. An open letter to Chairman Edward Kennedy and Senator Mike Enzi, Chairman John Dingell and Representative Joe Barton, Members of the Senate Health, Education, Labor and Pensions Committee, Members of House Energy and Commerce Committee. March 14, 2007. (Accessed April 5, 2007, at http://www.defendingscience.org.)